13,880 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,880 shares of the company's stock, valued at approximately $769,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $25,000. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $53,000. Quarry LP acquired a new position in Tarsus Pharmaceuticals in the 4th quarter valued at about $166,000. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals in the 4th quarter valued at about $207,000. Finally, Summit Investment Advisors Inc. increased its stake in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after purchasing an additional 244 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Activity at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now directly owns 70,720 shares of the company's stock, valued at approximately $3,273,628.80. The trade was a 9.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now directly owns 50,751 shares in the company, valued at approximately $2,349,263.79. This trade represents a 4.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 over the last ninety days. Insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Stock Down 4.8 %

TARS stock traded down $2.27 during trading on Friday, hitting $44.87. 529,648 shares of the company's stock were exchanged, compared to its average volume of 689,361. The business has a 50-day moving average price of $48.26 and a two-hundred day moving average price of $49.14. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -11.78 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TARS shares. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Jefferies Financial Group increased their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $66.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.